Literature DB >> 26303804

Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.

Scott K Heysell1, Suporn Pholwat2, Stellah G Mpagama3, Saumu J Pazia4, Happy Kumburu4, Norah Ndusilo4, Jean Gratz2, Eric R Houpt2, Gibson S Kibiki4.   

Abstract

MIC testing for Mycobacterium tuberculosis is now commercially available. Drug susceptibility testing by the MycoTB MIC plate has not been directly compared to that by the Bactec MGIT 960. We describe a case of extensively drug-resistant tuberculosis (XDR-TB) in Tanzania where initial MIC testing may have prevented acquired resistance. From testing on archived isolates, the accuracy with the MycoTB plate was >90% for important first- and second-line drugs compared to that with the MGIT 960, and clinically useful quantitative interpretation was also provided.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26303804      PMCID: PMC4604373          DOI: 10.1128/AAC.01117-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 2.  The future of molecular diagnostics for drug-resistant tuberculosis.

Authors:  Scott K Heysell; Eric R Houpt
Journal:  Expert Rev Mol Diagn       Date:  2012-05       Impact factor: 5.225

3.  Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Authors:  Stellah G Mpagama; Norah Ndusilo; Suzanne Stroup; Happiness Kumburu; Charles A Peloquin; Jean Gratz; Eric R Houpt; Gibson S Kibiki; Scott K Heysell
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

4.  Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory.

Authors:  Sayera Banu; S M Mazidur Rahman; M Siddiqur Rahman Khan; Sara Sabrina Ferdous; Shahriar Ahmed; Jean Gratz; Suzanne Stroup; Suporn Pholwat; Scott K Heysell; Eric R Houpt
Journal:  J Clin Microbiol       Date:  2013-10-30       Impact factor: 5.948

5.  Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment.

Authors:  Giovanni Sotgiu; Jan-Willem C Alffenaar; Rosella Centis; Lia D'Ambrosio; Antonio Spanevello; Andrea Piana; Giovanni Battista Migliori
Journal:  Int J Infect Dis       Date:  2015-03       Impact factor: 3.623

6.  Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance.

Authors:  K M Kam; A Sloutsky; C W Yip; N Bulled; K J Seung; M Zignol; M Espinal; S J Kim
Journal:  Int J Tuberc Lung Dis       Date:  2010-03       Impact factor: 2.373

7.  Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

Authors:  J Peter Cegielski; Tracy Dalton; Martin Yagui; Wanpen Wattanaamornkiet; Grigory V Volchenkov; Laura E Via; Martie Van Der Walt; Thelma Tupasi; Sarah E Smith; Ronel Odendaal; Vaira Leimane; Charlotte Kvasnovsky; Tatiana Kuznetsova; Ekaterina Kurbatova; Tiina Kummik; Liga Kuksa; Kai Kliiman; Elena V Kiryanova; HeeJin Kim; Chang-ki Kim; Boris Y Kazennyy; Ruwen Jou; Wei-Lun Huang; Julia Ershova; Vladislav V Erokhin; Lois Diem; Carmen Contreras; Sang Nae Cho; Larisa N Chernousova; Michael P Chen; Janice Campos Caoili; Jaime Bayona; Somsak Akksilp
Journal:  Clin Infect Dis       Date:  2014-07-23       Impact factor: 9.079

8.  Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs.

Authors:  Jongseok Lee; Derek T Armstrong; Willy Ssengooba; Jeong-Ae Park; Yeuni Yu; Francis Mumbowa; Carolyn Namaganda; Gerald Mboowa; Germine Nakayita; Sandra Armakovitch; Gina Chien; Sang-Nae Cho; Laura E Via; Clifton E Barry; Jerrold J Ellner; David Alland; Susan E Dorman; Moses L Joloba
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

9.  Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.

Authors:  Scott K Heysell; Shahriar Ahmed; Sara Sabrina Ferdous; Md Siddiqur Rahman Khan; S M Mazidur Rahman; Jean Gratz; Md Toufiq Rahman; Asif Mujtaba Mahmud; Eric R Houpt; Sayera Banu
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

10.  Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.

Authors:  Norah D Ndusilo; Scott K Heysell; Stellah G Mpagama; Jean Gratz; Farida H Segesela; Saumu J Pazia; Xin-Qun Wang; Eric R Houpt; Gibson S Kibiki
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

View more
  29 in total

1.  In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Authors:  J A Dijkstra; T van der Laan; O W Akkerman; M S Bolhuis; W C M de Lange; J G W Kosterink; T S van der Werf; J W C Alffenaar; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Xia Yu; Xiling Zeng; Wenhui Shi; Yanjie Hu; Wenjuan Nie; Naihui Chu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 3.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

4.  Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Authors:  Jan-Willem C Alffenaar; Simon Tiberi; Roger K Verbeeck; Scott K Heysell; Martin P Grobusch
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

5.  Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study.

Authors:  Christopher Vinnard; Liza King; Sonal Munsiff; Aldo Crossa; Kentaro Iwata; Jotam Pasipanodya; Douglas Proops; Shama Ahuja
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

6.  Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

Authors:  R van Altena; J A Dijkstra; M E van der Meer; J F Borjas Howard; J G W Kosterink; D van Soolingen; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

7.  Comparison of TaqMan(®) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB.

Authors:  S Foongladda; S Banu; S Pholwat; J Gratz; S O-Thong; N Nakkerd; R Chinli; S S Ferdous; S M M Rahman; A Rahman; S Ahmed; S Heysell; M Sariko; G Kibiki; E Houpt
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

8.  Prothionamide susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTECMGIT 960 system.

Authors:  Y Tan; B Su; H Zheng; Y Wang; Y Pang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-20       Impact factor: 3.267

9.  Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Authors:  Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Shashikant Srivastava; Paula Bendet; Thearith Koeuth; Pooi S Lee; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

10.  Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.

Authors:  Mohammad H Al-Shaer; Anne-Grete Märtson; Wael A Alghamdi; Abdullah Alsultan; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Eric R Houpt; David Ashkin; David E Griffith; J Peter Cegielski; Scott K Heysell; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.